Financing ·
Atrium Therapeutics amends filing to correct post-offering share count to 21.57M
RNAAtrium Therapeutics, Inc.
Atrium Therapeutics filed an amendment to a previous current report to correct the number of shares outstanding following its private placement offering. The company sold 5,170,384 shares of common stock and pre-funded warrants for up to 1,134,930 additional shares to accredited investors. Following the transaction, which includes shares issued for make whole equity awards related to its spin-off from Avidity Biosciences, the company has 21,571,507 shares outstanding. The filing corrects a previously disclosed figure but does not alter the terms of the offering or the capital raised. Atrium Therapeutics operates in the biotechnology industry, focusing on developing RNA-based therapeutics.